Kimmtrak to treat uveal melanoma
Drug Name: Kimmtrak Indications: To treat unresectable or metastatic uveal melanoma. Active Ingredient: Tebentafusp-tebn Company: Immunocore Commercial LLC Approval Date: 1/25/2022 More Details: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kimmtrak